Pharmacyte Biotech Stock Earnings Per Share
| PMCB Stock | USD 2.20 0.08 3.77% |
PharmaCyte Biotech fundamentals help investors to digest information that contributes to PharmaCyte Biotech's financial success or failures. It also enables traders to predict the movement of PharmaCyte Stock. The fundamental analysis module provides a way to measure PharmaCyte Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to PharmaCyte Biotech stock.
PharmaCyte | Earnings Per Share |
PharmaCyte Biotech Company Earnings Per Share Analysis
PharmaCyte Biotech's Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Current PharmaCyte Biotech Earnings Per Share | (1.48) X |
Most of PharmaCyte Biotech's fundamental indicators, such as Earnings Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, PharmaCyte Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
PharmaCyte Earnings Per Share Driver Correlations
Understanding the fundamental principles of building solid financial models for PharmaCyte Biotech is extremely important. It helps to project a fair market value of PharmaCyte Stock properly, considering its historical fundamentals such as Earnings Per Share. Since PharmaCyte Biotech's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of PharmaCyte Biotech's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of PharmaCyte Biotech's interrelated accounts and indicators.
Click cells to compare fundamentals
Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.
| Competition |
PharmaCyte Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
According to the company disclosure, PharmaCyte Biotech has an Earnings Per Share of -1.48 times. This is 117.68% lower than that of the Biotechnology sector and 69.1% lower than that of the Health Care industry. The earnings per share for all United States stocks is 147.44% higher than that of the company.
PharmaCyte Earnings Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses PharmaCyte Biotech's direct or indirect competition against its Earnings Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of PharmaCyte Biotech could also be used in its relative valuation, which is a method of valuing PharmaCyte Biotech by comparing valuation metrics of similar companies.PharmaCyte Biotech is currently under evaluation in earnings per share category among related companies.
PharmaCyte Biotech Current Valuation Drivers
We derive many important indicators used in calculating different scores of PharmaCyte Biotech from analyzing PharmaCyte Biotech's financial statements. These drivers represent accounts that assess PharmaCyte Biotech's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of PharmaCyte Biotech's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 34.3M | 39.7M | 36.2M | 56.9M | 51.2M | 27.8M | |
| Enterprise Value | 33.5M | 37.6M | (49.2M) | (11.1M) | (10.0M) | (9.5M) |
PharmaCyte Fundamentals
| Return On Equity | -0.0174 | ||||
| Return On Asset | -0.0524 | ||||
| Current Valuation | (20.46 M) | ||||
| Shares Outstanding | 8.45 M | ||||
| Shares Owned By Insiders | 8.11 % | ||||
| Shares Owned By Institutions | 15.05 % | ||||
| Number Of Shares Shorted | 45.73 K | ||||
| Price To Earning | 9.57 X | ||||
| Price To Book | 0.60 X | ||||
| EBITDA | (4.32 M) | ||||
| Net Income | (4.32 M) | ||||
| Cash And Equivalents | 82.23 M | ||||
| Cash Per Share | 3.96 X | ||||
| Total Debt | 3.34 K | ||||
| Current Ratio | 75.51 X | ||||
| Book Value Per Share | 3.68 X | ||||
| Cash Flow From Operations | (3.79 M) | ||||
| Short Ratio | 0.98 X | ||||
| Earnings Per Share | (1.48) X | ||||
| Beta | -0.16 | ||||
| Market Capitalization | 18.6 M | ||||
| Total Asset | 73.28 M | ||||
| Retained Earnings | (115.96 M) | ||||
| Working Capital | 67.56 M | ||||
| Current Asset | 1.6 M | ||||
| Current Liabilities | 449 K | ||||
| Net Asset | 73.28 M |
About PharmaCyte Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze PharmaCyte Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of PharmaCyte Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of PharmaCyte Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as PharmaCyte Biotech using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out PharmaCyte Biotech Piotroski F Score and PharmaCyte Biotech Altman Z Score analysis. For information on how to trade PharmaCyte Stock refer to our How to Trade PharmaCyte Stock guide.Note that the PharmaCyte Biotech information on this page should be used as a complementary analysis to other PharmaCyte Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Complementary Tools for PharmaCyte Stock analysis
When running PharmaCyte Biotech's price analysis, check to measure PharmaCyte Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PharmaCyte Biotech is operating at the current time. Most of PharmaCyte Biotech's value examination focuses on studying past and present price action to predict the probability of PharmaCyte Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PharmaCyte Biotech's price. Additionally, you may evaluate how the addition of PharmaCyte Biotech to your portfolios can decrease your overall portfolio volatility.
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |
Is PharmaCyte Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PharmaCyte Biotech. If investors know PharmaCyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PharmaCyte Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.48) | Return On Assets (0.05) | Return On Equity (0.02) |
The market value of PharmaCyte Biotech is measured differently than its book value, which is the value of PharmaCyte that is recorded on the company's balance sheet. Investors also form their own opinion of PharmaCyte Biotech's value that differs from its market value or its book value, called intrinsic value, which is PharmaCyte Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PharmaCyte Biotech's market value can be influenced by many factors that don't directly affect PharmaCyte Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PharmaCyte Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if PharmaCyte Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PharmaCyte Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.